Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...

Chronic Kidney Disease IV: Nursing Management

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preliminary Effects of Hydrogen-Oxygen Inhalation on Nodule Size, IL-6, and Neutrophils in Patients with Small Pulmonary Nodules.

Drug design, development and therapy·2026

Same author

Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure Infections.

Open forum infectious diseases·2026

Same author

Pannexin 1 attenuates hepatic steatosis and insulin resistance via AMPK-autophagy axis activation.

Cellular and molecular life sciences : CMLS·2026

Same author

KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα.

Metabolism: clinical and experimental·2026

Same author

Synergistic PNS-NAC Bioadhesive Microspheres for Enhanced Intestinal Permeability and Oral Bioavailability.

Recent advances in drug delivery and formulation·2026

Same author

Systematic Proteomic Characterization of EV-A71-Infected Mice Identifies Dynamic Molecular Changes and Therapeutic Targets.

MedComm·2026

Search research articles

Related Experiment Video

Updated: Sep 5, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement Therapy.

Xiaohui Wei¹, Shabnam Naseer², Edward A Weinstein^2,3

¹Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Clinical Pharmacology and Therapeutics

|July 6, 2022

Summary

This study establishes cefiderocol dosing for continuous renal replacement therapy (CRRT) using effluent flow rate (Q_E). The new method ensures similar cefiderocol pharmacokinetic profiles in CRRT patients compared to those without renal replacement therapy.

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Experiment Videos

Last Updated: Sep 5, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Area of Science:

Pharmacology
Nephrology
Infectious Diseases

Background:

Continuous renal replacement therapy (CRRT) alters drug pharmacokinetics, necessitating specific dosing adjustments.
Cefiderocol, an antibiotic, requires precise dosing in critically ill patients with renal impairment.
Current product labeling lacks specific cefiderocol dosing guidelines for patients undergoing CRRT.

Purpose of the Study:

To develop and validate an effluent flow rate (Q_E)-based dosing strategy for cefiderocol in patients receiving CRRT.
To ensure cefiderocol exposure in CRRT patients approximates that in non-CRRT patients.
To inform product labeling with evidence-based CRRT dosing recommendations.

Main Methods:

Estimated total cefiderocol clearance (CL) as the sum of nonrenal clearance (CL_nonrenal) and CRRT clearance (CL_CRRT).
Calculated CL_CRRT using the unbound fraction (f_u) and effluent flow rate (Q_E).
Conducted pharmacokinetic simulations to evaluate dosing regimens across clinically relevant Q_E ranges.

Main Results:

A novel equation, CL = CL_nonrenal + f_u × Q_E, was established for cefiderocol CL in CRRT patients.
Simulations confirmed that Q_E-based cefiderocol dosing achieves target exposure levels in CRRT patients.
The proposed dosing strategy resulted in pharmacokinetic profiles comparable to those in patients without CRRT.

Conclusions:

Effluent flow rate (Q_E)-based dosing is a viable strategy for cefiderocol in CRRT patients.
This approach supports optimized cefiderocol therapy and improved patient outcomes.
The findings provide a basis for updating cefiderocol product labeling for CRRT populations.